Sierra Oncology

NASDAQ SRRA
- - -%
Today share price
Canada
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 16 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

1.15B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

1.05B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

0.94
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

20.97M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

-

Upcoming events Sierra Oncology

All events
No upcoming events scheduled

Stock chart Sierra Oncology

Stock analysis Sierra Oncology

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

-11.23 28.88
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

12.01 4.03
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

-10.25 11.32
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

1.02 0.25
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

-39.24 10.75

Price change Sierra Oncology per year

11.66$ 23.22$
Min Max

Summary analysis Sierra Oncology

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Sierra Oncology

Revenue and net income Sierra Oncology

All parameters

Stock news Sierra Oncology

All news

Sareum Holdings Says Sierra Oncology To Return Cancer Treatment License; Shares Fall

Sareum Holdings Says Sierra Oncology To Return Cancer Treatment License; Shares Fall

Sareum Holdings Says GSK Completes Acquisition of Sierra Oncology

Sareum Holdings Says GSK Completes Acquisition of Sierra Oncology

Sierra Oncology downgraded to perform from outperform at Oppenheimer

Sareum Holdings Notes Glaxo Purchase of Treatment License Holder Sierra Oncology

Sareum Holdings Notes Glaxo Purchase of Treatment License Holder Sierra Oncology

GSK Buys Sierra Oncology for $1.9 Billion in Cancer Push

GSK to buy Sierra Oncology for $1.9 billion

Sierra Oncology Soars After Takeover by Glaxo

Sierra Oncology Soars After Takeover by Glaxo

Sierra Oncology Stock Soars After $1.9 Billion Takeover by GlaxoSmithKline

Sierra Oncology Stock Soars After $1.9 Billion Takeover by GlaxoSmithKline

GlaxoSmithKline to Acquire Sierra Oncology for $1.9 Bln -- Update

GlaxoSmithKline to Acquire Sierra Oncology for $1.9 Bln -- Update

GlaxoSmithKline to Acquire Sierra Oncology for $1.9 Bln

GlaxoSmithKline to Acquire Sierra Oncology for $1.9 Bln

Sierra Oncology Shares Rise Again, Extending Rally >SRRA

Sierra Oncology Shares Rise Again, Extending Rally >SRRA

Sierra Oncology Shares Soar Premarket on Momelotinib Study, Financing >SRRA

About company Sierra Oncology

Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.
Address:
1820 Gateway Drive, San Mateo, CA, United States, 94404
Company name: Sierra Oncology
Issuer ticker: SRRA
ISIN: US82640U4040
Country: Canada
Exchange: NASDAQ
Currency: $
IPO date: 2015-07-16
Sector: Healthcare
Industry: Biotechnology
Site: https://www.sierraoncology.com

On which stock exchange are Sierra Oncology (SRRA) stocks traded?

Sierra Oncology (SRRA) stocks are traded on NASDAQ.

What is the ticker of Sierra Oncology stocks (SRRA)?

The stock ticker of Sierra Oncology’s stocks or in other words, the code is SRRA. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Sierra Oncology (SRRA) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Sierra Oncology (SRRA) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Sierra Oncology (SRRA) stocks traded?

Sierra Oncology (SRRA) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Sierra Oncology (SRRA) stocks today?

The current price of Sierra Oncology stocks on 21.05.2024 is dollars. per share.

What is the dynamics of Sierra Oncology (SRRA) stocks from the beginning of the year?

Sierra Oncology (SRRA) quotes have increased by 0% from the beginning of the year up to dollars. per 1 stocks.

How much did Sierra Oncology (SRRA) stocks increase in мае 2024?

This month Sierra Oncology (SRRA) quotes have increased by 0% to dollars. per share.

How much are Sierra Oncology (SRRA) stocks worth?

Today, on October, 21.05.2024 Sierra Oncology’s (SRRA) stocks cost dollars..

What is the market capitalization of Sierra Oncology (SRRA)?

Capitalization is the market value of Sierra Oncology (SRRA) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 21.05.2024, the market capitalization of Sierra Oncology (SRRA) is estimated at about 1152909947 dollars.